Acera Surgical, Inc.

Acera Surgical is a bioscience company commercializing a portfolio of fully synthetic electrospun scaffolds for regenerative medical applications.

  • Stage $500K in TTM Revenue
  • Industry Nanotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Founded January 2013
  • Employees 5
  • Incorporation Type C-corp
  • Website acera-surgical.com

Company Summary

Acera Surgical, Inc. (“Acera”) is a bioscience company commercializing a portfolio of fully synthetic electrospun scaffolds for regenerative medical applications. Acera’s products exhibit a structure similar to native ECM and thus support rapid and effective healing. The FDA cleared Acera’s first product (Cerafix®) in March 2016 and its second product (Restrata) in April 2017, both via 510(k), granting commercial access to markets >$1.2B.

Team

  • Agnes Rey-Giraud
    Chief Executive Officer

    Agnès, a former Officer of Express Scripts, was a driving force behind many of the company’s key strategic initiatives and an influential player in the transformation of the company from a $4B to $44B enterprise, serving key roles in Product Dvlmnt, Supply Chain, Corporate Strategy and International Operations. Agnes holds an MBA from the University of Chicago and earned a Master of Science in Mechanical Engineering from ENISE, France.

  • Tamas Kovacs
    Senior Director, Product Management

    Prior to joining Acera, Tamas spent 2 years in China as a project manager for Express Scripts, Inc. After earning a bachelor’s degree in Operations Research and Industrial Engineering, Tamas received a Masters of Engineering in Engineering Management, both degrees from Cornell University.

  • Julie Cochran
    Chief Operating Officer

    Julie earned an MBA from the Stanford Graduate School of Business and graduated summa cum laude with a BSE in both Biomedical Engineering and Electrical Engineering from Duke University. While at McKinsey, Julie served clients throughout the healthcare sector, including pharmaceutical, medical device, biotechnology and payer/provider. She also held multiple roles as a VP at Express Scripts, including Corporate Strategy and Product Dvlmnt/Mgmt.

  • Dr. Matthew MacEwan
    Co-Founder/Chief Scientific Officer

    Matthew is the co-inventor of Acera’s technology and graduated summa cum laude with a degree in BME from Case Western Reserve Univ. with a specialization in polymer biomaterials/biomaterial biocompatibility and received his PhD in BME from Washington University where he also received his MD training. Matthew received multiple entrepreneurship awards, including the 2011 Olin Cup Award & the 2011 LES Global Business Plan Competition Grand Prize.

Advisors

Previous Investors

  • Washington University in St. Louis
    Unconfirmed
    Private Investors
    Unconfirmed
    Missouri Technology Corporation
    Unconfirmed
  • Arch Angels (via Acera Angels LLC)
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free